background
diagnost
epidemiolog
clinic
featur
recent
discov
human
metapneumoviru
remain
investig
object
studi
best
approach
diagnosi
human
metapneumoviru
infect
convent
molecular
method
along
human
metapneumoviru
circul
rate
northern
itali
sever
human
metapneumoviru
respiratori
infect
pediatr
patient
popul
studi
design
nasopharyng
aspir
npa
taken
pediatr
patient
winterspr
season
examin
convent
respiratori
virus
direct
fluoresc
stain
cell
cultur
human
coronaviru
human
metapneumoviru
sought
rtpcr
result
rtpcr
detect
human
metapneumoviru
children
posit
respiratori
virus
incid
intermedi
respiratori
syncyti
viru
patient
influenzaviru
infect
patient
phylogenet
analysi
show
cocircul
human
metapneumoviru
type
b
well
relev
subtyp
clinic
human
metapneumoviru
found
second
human
respiratori
syncyti
viru
alon
caus
respiratori
tract
infect
durat
viru
excret
appear
correl
sever
infect
viru
load
npa
stage
respiratori
infect
conclus
human
metapneumoviru
major
viral
pathogen
italian
pediatr
patient
popul
ii
sever
lower
respiratori
tract
infect
approach
human
respiratori
syncyti
viru
iii
preliminari
indic
durat
viru
excret
may
reach
week
level
viral
load
npa
correl
clinic
stage
human
metapneumoviru
infect
follow
origin
report
van
den
hoogen
et
al
human
metapneumoviru
repeatedli
abbrevi
rtpcr
revers
transcriptionpcr
cpe
cytopath
effect
npa
nasopharyng
aspir
mab
monoclon
antibodi
sagmk
secondari
african
green
monkey
kidney
helf
human
embryon
lung
fibroblast
elisa
enzymelink
immunosorb
assay
correspond
author
tel
fax
email
address
ggerna
smatteopvit
g
gerna
report
respiratori
pathogen
earli
infanc
well
elderli
immunocompromis
host
bastien
et
al
chan
et
al
falsey
et
al
maggi
et
al
van
den
hoogen
et
al
william
et
al
known
human
metapneumoviru
member
van
den
hoogen
et
al
famili
paramyxovirida
subfamili
pneumovirina
human
respiratori
syncyti
viru
belong
differ
genu
metapneumoviru
instead
pneumoviru
major
reason
human
metapneumoviru
recov
previous
respiratori
specimen
due
difficulti
grow
cell
cultur
convent
adopt
isol
respiratori
virus
recent
identif
human
metapneumoviru
first
netherland
countri
made
possibl
use
molecular
assay
particular
revers
transcriptionpolymeras
chain
reaction
rtpcr
sinc
initi
public
van
den
hoogen
et
al
two
major
cluster
b
human
metapneumoviru
detect
rtpcr
report
cocircul
although
develop
monoclon
antibodi
mab
diagnost
use
perform
landri
et
al
percival
et
al
mab
direct
antigen
detect
nasopharyng
aspir
npa
sampl
commerci
avail
thu
molecular
assay
repres
major
approach
current
avail
human
metapneumoviru
identif
although
human
metapneumoviru
consid
major
caus
upper
lower
respiratori
tract
infect
rti
sever
aspect
human
metapneumoviru
infect
remain
defin
particular
sever
human
metapneumoviru
infect
entir
defin
correl
viral
load
npa
sever
clinic
diseas
yet
establish
nissen
et
al
bastien
et
al
greensil
et
al
maggi
et
al
viazov
et
al
esper
et
al
hamelin
et
al
william
et
al
van
den
hoogen
et
al
addit
durat
viru
excret
acut
infect
remain
defin
furthermor
paramyxovirus
glezen
et
al
human
respiratori
syncyti
viru
human
metapneumoviru
reinfect
report
immunocompet
van
den
hoogen
et
al
esper
et
al
immunocompromis
host
yet
find
await
confirm
present
report
follow
major
issu
address
take
advantag
high
circul
human
metapneumoviru
winterspr
season
circul
rate
human
metapneumoviru
among
respiratori
virus
northern
itali
ii
sever
human
metapneumoviru
lower
respiratori
tract
infect
compar
human
respiratori
syncyti
viru
iii
durat
human
metapneumoviru
excret
relationship
viral
load
npa
stage
human
metapneumoviru
infect
decemb
may
npa
sampl
collect
prospect
depart
pediatr
univers
pavia
ircc
policlinico
san
matteo
pavia
itali
infant
young
children
acut
respiratori
infect
admit
emerg
section
depart
patient
dismiss
day
follow
complet
clinic
laboratori
radiolog
test
wherea
other
admit
respiratori
diseas
ward
sever
clinic
present
npa
sampl
divid
four
aliquot
first
use
molecular
assay
second
use
direct
fluoresc
antibodi
stain
npa
respiratori
cell
third
inocul
onto
cell
cultur
viru
isol
see
fourth
frozen
multipl
aliquot
backup
sampl
specimen
examin
influenzavirus
b
parainfluenzavirus
type
human
respiratori
syncyti
viru
type
b
human
adenovirus
direct
fluoresc
antibodi
stain
shortand
longterm
viru
isol
cell
cultur
addit
human
coronaviru
strain
group
ii
human
metapneumovirus
type
b
sought
rtpcr
classif
type
human
respiratori
syncyti
viru
strain
achiev
rtpcr
group
human
coronaviru
strain
sequenc
type
human
metapneumoviru
strain
sequenc
phylogenet
analysi
see
studi
approv
ircc
policlinico
san
matteo
ethic
committe
studi
simultan
detect
two
respiratori
virus
npa
refer
coinfect
subsequ
identif
two
differ
respiratori
virus
two
npa
taken
within
day
consid
sequenti
infect
rtpcr
assay
identif
respiratori
virus
optim
detect
least
input
plasmid
copi
purpos
primer
either
select
publish
protocol
origin
design
genbank
publish
viru
sequenc
amplif
product
clone
plasmid
vector
ta
clone
kit
invitrogen
carlsbad
ca
prepar
quantit
standard
addit
report
thermal
profil
reaction
mixtur
modifi
virus
pcr
protocol
redesign
experiment
verifi
virus
respiratori
virus
amplifi
use
pcr
protocol
deriv
publish
paper
follow
influenzavirus
b
stockton
et
al
human
parainfluenza
echevarria
et
al
human
respiratori
syncyti
viru
type
b
coira
et
al
human
adenoviru
allard
et
al
human
metapneumoviru
type
l
gene
nt
accord
van
den
hoogen
et
al
human
coronaviru
group
ii
accord
poutanen
et
al
newli
design
primer
pair
influenzaviru
human
parainfluenza
human
parainfluenza
human
metapneumoviru
type
b
gene
l
type
b
gene
n
well
amplifi
fragment
target
gene
amplicon
size
thermal
profil
cycl
number
relev
virus
report
tabl
pcr
reaction
perform
report
rovida
et
al
nucleic
acid
extract
tabl
inhous
defin
pcr
paramet
detect
respiratori
virus
present
nasopharyng
aspir
sampl
viru
use
nuclisen
iso
kit
biomerieux
lyon
franc
pcr
product
examin
agaros
gel
direct
fluoresc
antibodi
stain
appli
slide
contain
suffici
number
cytocentrifug
respiratori
epitheli
columnar
cell
stain
pool
simulfluor
respiratori
screen
reagent
chemicon
intern
inc
temecula
ca
fluoresceinlabel
mab
convent
respiratori
virus
influenza
b
human
parainfluenza
viru
human
respiratori
syncyti
viru
human
adenoviru
singl
fluoresceinconjug
mab
includ
pool
individu
convent
respiratori
virus
obtain
sourc
chemicon
addit
mab
human
coronaviru
chemicon
preliminarili
found
perform
satisfactorili
identifi
refer
strain
well
npaposit
sampl
wherea
mab
human
coronaviru
thu
abandon
mab
human
metapneumoviru
found
commerci
avail
npa
sampl
process
cell
cultur
inocul
onto
two
shell
vial
mixtur
mix
ratio
cell
huang
turchek
rapid
viru
detect
well
onto
two
tube
mdck
cell
line
recoveri
convent
respiratori
virus
cell
cultur
shell
vial
centrifug
rpm
min
incub
c
co
atmospher
h
one
shell
vial
fix
stain
mab
direct
fluoresc
antibodi
stain
case
neg
result
second
shell
vial
stain
day
pi
convent
viru
isol
mdck
cell
inocul
npa
sampl
incub
c
observ
daili
cpe
day
cell
trypsin
one
tube
stain
mab
direct
fluoresc
antibodi
stain
case
neg
result
cultur
second
tube
kept
observ
two
addit
week
preliminari
experi
follow
cell
cultur
use
human
metapneumoviru
recoveri
secondari
agmk
sagmk
human
embryon
lung
fibroblast
helf
vero
subsequ
select
optim
viru
isol
propag
inhous
prepar
guinea
pig
hyperimmun
serum
use
human
metapneumoviru
identif
type
b
cell
cultur
adapt
growth
cell
cultur
human
metapneumoviru
quantifi
cpe
tissu
cultur
infecti
dose
tcid
serial
tenfold
dilut
infect
supernat
harvest
day
pi
addit
human
metapneumoviru
rna
cell
cultur
supernat
npa
semiquantifi
follow
rt
dilut
viral
cdna
origin
sampl
great
major
human
metapneumoviru
strain
studi
classifi
type
b
accord
recent
report
van
den
hoogen
et
al
differ
anoth
recent
paper
boivin
et
al
classif
type
appar
invert
viral
sequenc
amplifi
gene
n
fragment
nt
human
metapneumoviru
isol
well
refer
strain
align
clustal
w
program
version
wherea
sequenc
similar
comparison
carri
megalign
program
dnastar
inc
madison
wi
distanc
pair
nucleotid
sequenc
calcul
use
dnadist
kimura
twoparamet
method
modul
philip
packag
version
felsenstein
depart
genet
univers
washington
seattl
wa
percent
genet
ident
within
n
gene
calcul
four
major
branch
tree
philip
njplot
program
use
construct
phylogenet
tree
nucleotid
sequenc
mean
neighbourjoin
method
distanc
matric
bootstrap
support
determin
resampl
sequenc
studi
observ
human
metapneumoviru
strain
type
detect
use
primer
pair
origin
publish
gene
l
amplif
van
den
hoogen
et
al
thu
origin
primer
pair
kept
detect
type
strain
new
primer
set
match
nt
posit
design
basi
gene
l
sequenc
publish
genbank
type
b
strain
result
sever
type
b
strain
could
detect
retrospect
patient
seri
alreadi
examin
start
march
patient
prospect
investig
use
pair
primer
mixtur
addit
fragment
human
metapneumoviru
gene
n
nt
amplifi
confirm
result
obtain
amplifi
gene
l
construct
phylodendrogram
use
degener
primer
report
tabl
initi
follow
inocul
two
npa
sampl
strongli
posit
human
metapneumoviru
rtpcr
viru
isol
attempt
follow
overnight
adsorpt
sagmk
vero
fed
emem
contain
trypsin
gml
absenc
fetal
calf
serum
inocul
cell
cultur
incub
c
tabl
posit
rtpcr
signal
detect
supernat
three
cell
cultur
type
day
inocul
follow
first
passag
whole
cell
cultur
cell
supernat
onto
homolog
cell
viral
rna
signal
increas
sagmk
markedli
decreas
vero
cell
upon
second
passag
rna
signal
increas
sagmk
disappear
vero
cell
time
propag
two
human
metapneumoviru
isol
onto
helf
attempt
shown
tabl
attempt
fail
helf
two
passag
success
human
metapneumoviru
strain
viru
semiquantifi
viral
rna
rtpcr
quantifi
infect
titer
cpe
follow
h
follow
h
adsorpt
extens
wash
viru
titer
parallel
serial
tenfold
dilut
rna
semiquantit
infect
tcid
day
peak
titer
log
rna
copiesml
tcid
ml
detect
rna
cpe
respect
thu
peak
rna
titer
detect
week
advanc
respect
infect
titer
adsorpt
extens
wash
viral
rna
start
appear
medium
pi
fig
reach
log
rna
copiesml
day
stabl
peak
rna
titer
log
rna
copiesml
day
fig
base
cpe
infect
titer
reach
log
tcid
ml
day
log
day
log
day
fig
thu
day
mean
viral
titer
measur
either
cpe
rna
howev
viral
rna
peak
titer
within
limit
semiquantit
endpoint
dilut
reach
week
advanc
respect
infect
peak
titer
sequenc
first
fragment
gene
n
nt
subsequ
phylogenet
analysi
human
metapneumoviru
strain
recov
winter
season
show
type
b
human
metapneumoviru
well
relev
subtyp
circul
northern
itali
fig
howev
base
analysi
human
metapneumoviru
strain
circul
rate
differ
differ
subtyp
follow
n
strain
n
n
n
strain
phylogenet
tree
drawn
use
follow
refer
strain
among
pediatr
patient
examin
winterspr
season
posit
one
respiratori
virus
either
immunolog
molecular
method
fig
patient
affect
singl
infect
human
respiratori
syncyti
viru
human
metapneumoviru
influenzavirus
influenza
influenza
b
human
coronaviru
human
adenoviru
human
parainfluenza
viru
addit
patient
affect
coinfect
human
metapneumovirus
human
coronaviru
human
metapneumovirus
type
human
coronaviru
human
metapneumoviru
type
b
human
coronaviru
human
metapneumoviru
type
influenza
human
metapneumovirus
type
human
adenoviru
human
respiratori
syncyti
viru
type
b
influenza
human
respiratori
syncyti
viru
human
adenoviru
influenza
b
human
coronaviru
influenza
human
adenoviru
patient
affect
sequenti
respiratori
viru
infect
human
metapneumoviru
type
follow
human
respiratori
syncyti
viru
human
metapneumoviru
type
follow
adenoviru
influenza
follow
human
metapneumoviru
type
human
metapneumoviru
type
b
follow
human
respiratori
syncyti
viru
human
coronaviru
final
influenza
follow
human
respiratori
syncyti
viru
thu
overal
number
paediatr
patient
affect
human
metapneumoviru
infect
includ
coinfect
sequenti
infect
number
patient
human
respiratori
syncyti
viru
infect
includ
coinfect
sequenti
infect
number
patient
influenza
influenza
influenza
b
includ
coinfect
sequenti
infect
number
patient
human
coronaviru
infect
includ
coinfect
sequenti
infect
final
number
patient
human
adenoviru
infect
includ
coinfect
sequenti
infect
monthli
distribut
show
peak
human
respiratori
syncyti
viru
infect
march
peak
human
metapneumoviru
influenzaviru
infect
reach
februari
fig
human
respiratori
syncyti
viru
predomin
compar
human
metapneumoviru
januari
march
april
februari
rate
two
viru
infect
ident
case
observ
either
viru
incid
human
respiratori
syncyti
viru
human
metapneumoviru
infect
first
year
life
rel
proport
human
respiratori
syncyti
viru
human
metapneumoviru
infect
first
month
life
found
significantli
differ
p
circul
rate
type
human
metapneumoviru
infect
type
b
patient
type
human
respiratori
syncyti
viru
infect
type
b
human
respiratori
syncyti
viru
patient
distribut
eight
human
coronaviru
strain
examin
seven
group
one
group
ii
shown
fig
human
metapneumovirusinfect
children
examin
pediatr
emerg
depart
dismiss
outpati
medic
examin
admit
respiratori
diseas
ward
inpati
comparison
human
respiratori
syncyti
virusinfect
children
eight
outpati
mani
inpati
thu
document
significantli
higher
number
inpati
human
respiratori
syncyti
virusinfect
compar
human
metapneumovirusinfect
group
p
test
contrari
number
inpati
lower
respiratori
tract
infect
significantli
differ
two
group
patient
number
infant
doubl
infect
mostli
restrict
inpati
group
fig
whenev
possibl
patient
posit
human
metapneumoviru
npa
examin
human
metapneumoviru
respiratori
virus
npa
sampl
collect
follow
day
week
order
determin
durat
viral
excret
ii
correl
viral
load
clinic
symptom
preliminarili
observ
human
metapneumoviru
often
excret
respiratori
secret
day
detail
durat
human
metapneumoviru
excret
eight
children
undergo
multipl
sampl
followup
show
trend
toward
persist
viru
shed
week
patient
pneumonia
bronchiol
wherea
patient
upper
respiratori
tract
involv
shed
viru
mostli
less
day
addit
shown
patient
report
tabl
highest
viral
rna
titer
detect
concomitantli
peak
clinic
symptom
interest
either
upper
lower
respiratori
tract
decreas
viral
load
mostli
associ
resolut
local
clinic
symptom
extens
data
seem
suggest
drop
viral
titer
dissoci
resolut
clinic
symptom
may
help
exclud
etiolog
role
human
metapneumoviru
current
respiratori
infect
six
infant
young
children
test
presenc
viral
rna
serum
mean
day
first
viru
detect
npa
viru
detect
serum
patient
whether
human
metapneumoviru
still
present
npa
unfortun
serum
avail
test
time
first
viral
rna
detect
npa
present
report
circul
rate
human
metapneumoviru
among
respiratori
virus
caus
respiratori
tract
infect
hospit
children
winterspr
season
studi
gain
insight
diagnost
epidemiolog
clinic
aspect
human
metapneumoviru
infect
pediatr
patient
northern
itali
diagnosi
mostli
done
rtpcr
howev
other
maertzdorf
et
al
observ
strain
could
detect
rtpcr
method
use
primer
pair
origin
use
van
den
hoogen
et
al
human
metapneumoviru
detect
number
mismatch
respect
target
sequenc
four
genet
lineag
particularli
two
sublineag
b
fact
design
new
primer
pair
basi
publish
sequenc
gene
l
human
metapneumoviru
b
strain
new
seri
human
metapneumovirusposit
npa
sampl
identifi
among
previous
neg
respiratori
specimen
determin
use
primer
pair
subsequ
mixtur
two
primer
pair
routin
employ
human
metapneumoviru
detect
clinic
sampl
result
type
subtyp
b
human
metapneumoviru
strain
could
detect
respect
seem
import
recal
realtim
rtpcr
specif
gene
n
shown
sensit
rtpcr
specif
gene
l
f
p
human
metapneumoviru
strain
et
al
parallel
optim
cell
cultur
system
human
metapneumoviru
isol
investig
view
potenti
detect
human
metapneumoviru
type
strain
detect
rtpcr
human
metapneumoviru
detect
year
initi
medic
virolog
ie
introduct
cell
cultur
technolog
obviou
answer
question
recent
extend
use
molecular
techniqu
howev
tertiari
agmk
cell
cultur
essenti
initi
human
metapneumoviru
detect
respiratori
sampl
van
den
hoogen
et
al
subsequ
sever
group
report
human
metapneumoviru
isol
convent
cell
cultur
agmk
wellknown
cell
line
chan
et
al
hamelin
et
al
van
den
hoogen
et
al
recent
subclon
vero
cell
mention
particularli
suscept
human
metapneumoviru
isol
van
den
hoogen
et
al
studi
confirm
sensit
cell
cultur
system
human
metapneumoviru
cpe
detect
agmk
respect
cell
may
prefer
sinc
wide
avail
give
clearcut
although
delay
cpe
well
known
among
avian
mpv
ampv
four
differ
type
b
c
thu
far
identifi
suggest
parallel
cultur
molecular
approach
diagnosi
human
metapneumoviru
infect
may
desir
view
potenti
identif
new
human
metapneumoviru
type
phylogenet
analysi
human
metapneumoviru
strain
differ
countri
base
comparison
sequenc
gene
l
n
f
p
van
den
hoogen
et
al
boivin
et
al
boivin
et
al
bastien
et
al
mackay
et
al
consist
allow
cluster
strain
two
major
group
refer
b
major
group
two
subgroup
classif
initi
introduc
dutch
author
discov
human
metapneumoviru
van
den
hoogen
et
al
accept
group
keep
mind
start
point
classif
attempt
entir
genom
sequenc
prototyp
strain
report
subtyp
van
den
hoogen
et
al
recent
public
consid
prototyp
dutch
strain
belong
subgroup
may
gener
confus
limit
studi
restrict
singl
respiratori
viru
season
lack
detect
rhinovirus
sever
clinic
symptom
requir
admiss
hospit
within
limit
report
other
human
metapneumoviru
reach
peak
circul
februarymarch
togeth
human
respiratori
syncyti
viru
influenzavirus
highli
circul
viru
pediatr
patient
popul
human
respiratori
syncyti
viru
addit
human
metapneumoviru
larg
predomin
along
human
respiratori
syncyti
viru
first
year
life
epidemiolog
find
substanti
agreement
recent
publish
paper
van
den
hoogen
et
al
esper
et
al
mcadam
et
al
mullin
et
al
william
et
al
human
metapneumoviru
second
human
respiratori
syncyti
viru
circul
rate
sever
clinic
symptom
document
fact
unlik
patient
infect
virus
agreement
previou
report
bastien
et
al
maggi
et
al
number
human
respiratori
syncyti
virusinfect
significantli
greater
human
metapneumovirusinfect
inpati
rel
proport
inpati
lower
respiratori
tract
infect
well
number
children
doubl
infect
compar
two
group
howev
coinfect
sequenti
infect
appear
sever
prognost
factor
sinc
nearli
exclus
detect
inpati
durat
human
metapneumoviru
excret
appear
even
longer
previous
report
van
den
hoogen
et
al
may
repres
rout
viru
dissemin
resolut
acut
clinic
symptom
presenc
low
viral
load
npa
data
correl
viral
load
npa
clinic
symptom
support
conclus
fact
preliminari
observ
trend
toward
correl
level
viral
rna
load
npa
sampl
presenc
clinic
symptom
indic
amount
viru
present
respiratori
secret
direct
marker
etiolog
involv
human
metapneumoviru
current
respiratori
diseas
level
viral
rna
detect
respiratori
tract
acut
phase
respiratori
diseas
somewhat
compar
found
upper
respiratori
tract
experiment
infect
hamster
skiadopoulo
et
al
howev
import
recal
experiment
anim
model
includ
nonhuman
primat
mimic
human
metapneumoviru
diseas
even
though
high
level
neutral
antibodi
crossprotect
heterolog
strain
induc
macphail
et
al
skiadopoulo
et
al
case
human
metapneumoviru
infect
examin
blood
viral
rna
could
detect
contrast
data
recent
publish
maggi
et
al
find
could
explain
fact
examin
blood
day
onset
respiratori
infect
thu
viru
could
alreadi
clear
blood
presenc
respiratori
virus
virus
infect
mucos
tissu
blood
may
surpris
howev
may
help
recal
recent
influenzaviru
rna
human
adenoviru
dna
detect
blood
patient
acut
encephalopathi
associ
influenzaviru
infect
steining
et
al
addit
human
rotaviru
antigenemia
detect
blood
infant
acut
gastroenter
blutt
et
al
conclus
studi
demonstr
human
metapneumoviru
major
viral
pathogen
italian
paediatr
patient
popul
second
human
respiratori
syncyti
viru
ii
sever
human
metapneumoviru
infect
approach
human
respiratori
syncyti
viru
viru
excret
may
persist
even
week
iii
preliminari
indic
correl
human
metapneumoviru
load
respiratori
secret
stage
viral
infect
work
partial
support
ministero
della
salut
ricerca
finalizzata
convenzion
